CPIX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Cumberland Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 6.68 USD
1.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 40.4% above the Trend Line and sits at 77.4% of its 52-week range. The latest completed week returned 1.1%, after a 4.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. Options positioning is volatility with 62/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 1d.

Setup score 61 out of 100
Latest Close 6.68 USD 31 Jul 2026
1W Return 1.1% latest completed week
4W Return 4.9% short-term follow-through
12W Return 42.7% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 14-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.1% Latest completed week; four-week move 4.9%. Indicator stack 70/64 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 62/100 conviction; expected move 33.7%. News sentiment 57/100 50 relevant articles in the latest sentiment read. Event risk 1d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 40.4% above the Trend Line and sits at 77.4% of its 52-week range. The latest completed week returned 1.1%, after a 4.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8412-week average 0.57

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.84Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.9% over four weeks, 42.7% over 12 weeks, and 89.8% over one year. The current trend has remained active for 14 consecutive weeks.

Performance by holding period

1W1.1%
4W4.9%
12W42.7%
26W78.1%
52W89.8%
Active trend streak14 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.85Latest activity-pressure read.
Pressure change-19.3%Four-week change in activity pressure.
Leadership53.21Latest relative-leadership reading.
RS change12.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 80%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality71/100Profitability and accounting quality. Underlying universe rank 30; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth28/100Revenue and earnings growth. Underlying universe rank 73; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
1.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
82.9%
Gross profit retained from each unit of revenue.
Operating margin
-16.2%
Operating profit retained from revenue.
Free-cash-flow margin
3.6%
Free cash flow generated from revenue.
Return on invested capital
-24.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
2.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-72.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.1%
Net share repurchases relative to market value.
Shareholder yield
0.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CPIX shows volatility options pressure with a 62/100 conviction score, put-call volume ratio of 0.05, expected move of 33.7%, and Sharemaestro trend signal active.

Conviction62/100
Expected move33.7%
Put/call volume0.05
Pressure99
Speculation32
Volatility96
Trend agreement16
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment57/100

Weighted news tone is neutral across 50 relevant articles.

15 positive · 33 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings1dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move33.7%Nearest-chain priced movement where available.
52-week drawdown-17.4%Distance below the 52-week high.
13-week volatility8.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+26.2%Week of 27 Feb.
Worst week-28.9%Week of 6 Mar.
Latest week+1.1%Week of 31 Jul.

Shape of recent returns

Strong gains12
Modest gains4
Flat weeks0
Modest losses4
Sharp losses6
Recent vol8.5%13-week weekly-return volatility.
Base vol14.9%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew11.3% / -7.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape58/100

Trend, activity pressure, participation, and risk combine to a 58/100 tape read.

 Indicator analysis85/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.84; 2 reversal markers Factors57/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 42; Small Cap Core rank 84 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

CPIX shows volatility options pressure with a 62/100 conviction score, put-call volume ratio of 0.05, expected move of 33.7%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 33.7% Sentiment57/100

Weighted news tone is neutral across 50 relevant articles.

ETFs Investing in Cumberland Pharmaceuticals Inc. Stocks Insiders50/100

No recent insider transaction evidence is stored.

 Earnings1d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20266.68 USD1.1%4.76 USD2.97 USD0.8553.21395.5KOn
24 Jul 20266.61 USD-3.4%4.67 USD2.93 USD0.9053.99947.2KOn
17 Jul 20266.84 USD15.3%4.58 USD2.90 USD0.9758.47911.6KOn
10 Jul 20265.93 USD-6.9%4.50 USD2.87 USD0.9833.36199.0KOn
3 Jul 20266.37 USD-5.6%4.39 USD2.84 USD1.0647.12269.7KOn
26 Jun 20266.75 USD18.0%4.26 USD2.81 USD1.0358.87289.4KOn
19 Jun 20265.72 USD2.1%4.11 USD2.77 USD1.0030.57131.9KOn
12 Jun 20265.60 USD-3.4%3.98 USD2.75 USD0.9931.01232.9KOn
5 Jun 20265.80 USD-5.7%3.87 USD2.72 USD0.9337.83341.5KOn
29 May 20266.15 USD4.8%3.74 USD2.69 USD0.8238.32895.9KOn
22 May 20265.87 USD7.3%3.64 USD2.66 USD0.5935.30638.9KOn
15 May 20265.47 USD16.9%3.56 USD2.64 USD0.4326.87676.3KOn
8 May 20264.68 USD7.3%3.49 USD2.61 USD0.007.741.2MOn
1 May 20264.36 USD7.4%3.45 USD2.59 USD-0.334.871.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.